These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 33828220)
1. Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon. Abange WB; Martin C; Nanfack AJ; Yatchou LG; Nusbacher N; Nguedia CA; Kamga HG; Fokam J; Kennedy SP; Ndjolo A; Lozupone C; Nkenfou CN Sci Rep; 2021 Apr; 11(1):7666. PubMed ID: 33828220 [TBL] [Abstract][Full Text] [Related]
2. Composition of Gut Microbiota of Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection Taking Antiretroviral Therapy in Zimbabwe. Flygel TT; Sovershaeva E; Claassen-Weitz S; Hjerde E; Mwaikono KS; Odland JØ; Ferrand RA; Mchugh G; Gutteberg TJ; Nicol MP; Cavanagh JP; Flægstad T; J Infect Dis; 2020 Jan; 221(3):483-492. PubMed ID: 31549151 [TBL] [Abstract][Full Text] [Related]
3. Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens. Pinto-Cardoso S; Lozupone C; Briceño O; Alva-Hernández S; Téllez N; Adriana A; Murakami-Ogasawara A; Reyes-Terán G Sci Rep; 2017 Mar; 7():43741. PubMed ID: 28262770 [TBL] [Abstract][Full Text] [Related]
4. Exploring the interplay between antiretroviral therapy and the gut-oral microbiome axis in people living with HIV. Narayanan A; Kieri O; Vesterbacka J; Manoharan L; Chen P; Ghorbani M; Ljunggren HG; Sällberg Chen M; Aleman S; Sönnerborg A; Ray S; Nowak P Sci Rep; 2024 Aug; 14(1):17820. PubMed ID: 39090139 [TBL] [Abstract][Full Text] [Related]
5. Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine. Ray S; Narayanan A; Giske CG; Neogi U; Sönnerborg A; Nowak P ACS Infect Dis; 2021 May; 7(5):1104-1115. PubMed ID: 33346662 [TBL] [Abstract][Full Text] [Related]
6. Intestinal Parasites Infections among HIV Infected Children Under Antiretrovirals Treatment in Yaounde, Cameroon. Abange WB; Nkenfou CN; Gonsu Kamga H; Nguedia CA; Kamgaing N; Lozupone C; Sosso SM; Kamgaing R; Fosso S; Essomba A; Ndjolo A; Koki P J Trop Pediatr; 2020 Apr; 66(2):178-186. PubMed ID: 31325361 [TBL] [Abstract][Full Text] [Related]
7. Gut Microbiota Diversity in HIV-Infected Patients on Successful Antiretroviral Treatment is Linked to Sexual Preferences but not CD4 Nadir. Jabłonowska E; Strzelczyk J; Piekarska A; Wójcik-Cichy K Arch Immunol Ther Exp (Warsz); 2021 May; 69(1):14. PubMed ID: 33983543 [TBL] [Abstract][Full Text] [Related]
8. Thrombocytopenia according to antiretroviral drug combinations, viremia and CD4 lymphocytes among HIV-infected patients in Cameroon: a snapshot from the City of Yaoundé. Nka AD; Sosso SM; Fokam J; Bouba Y; Teto G; Simo Rachel R; Tiga A; Yimga J; Nukenine EN; Nanfack AJ; Takou D; Aroga Z; Colizzi V; Ndjolo A BMC Res Notes; 2019 Sep; 12(1):632. PubMed ID: 31554515 [TBL] [Abstract][Full Text] [Related]
9. Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study. Sainz T; Gosalbes MJ; Talavera-Rodríguez A; Jimenez-Hernandez N; Prieto L; Escosa L; Guillén S; Ramos JT; Muñoz-Fernández MÁ; Moya A; Navarro ML; Mellado MJ; Serrano-Villar S Nutrients; 2020 Jul; 12(7):. PubMed ID: 32708743 [TBL] [Abstract][Full Text] [Related]
10. Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe. Burkhart Colorado AS; Lazzaro A; Neff CP; Nusbacher N; Boyd K; Fiorillo S; Martin C; Siebert JC; Campbell TB; Borok M; Palmer BE; Lozupone C Microbiome; 2024 Feb; 12(1):18. PubMed ID: 38310301 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of protease inhibitor-based antiretroviral therapy amongst children and associated-factors in Yaoundé, Cameroon. Njom Nlend AE; Guessong CO; Nga Motaze AC; Soffo C; Koki Ndombo PO; Tsambang L; Fokam J PLoS One; 2019; 14(3):e0213900. PubMed ID: 30883591 [TBL] [Abstract][Full Text] [Related]
12. Evidence for extended age dependent maternal immunity in infected children: mother to child transmission of HIV infection and potential interventions including sulfatides of the human fetal adnexa and complementary or alternative medicines. Bhargav H; Huilgol V; Metri K; Sundell IB; Tripathi S; Ramagouda N; Jadhav M; Raghuram N; Ramarao NH; Koka PS J Stem Cells; 2012; 7(3):127-53. PubMed ID: 23619381 [TBL] [Abstract][Full Text] [Related]
13. A gut check: understanding the interplay of the gastrointestinal microbiome and the developing immune system towards the goal of pediatric HIV remission. Soo N; Farinre O; Chahroudi A; Boliar S; Goswami R Retrovirology; 2024 Oct; 21(1):15. PubMed ID: 39425183 [TBL] [Abstract][Full Text] [Related]
14. High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy. Kaur US; Shet A; Rajnala N; Gopalan BP; Moar P; D H; Singh BP; Chaturvedi R; Tandon R Sci Rep; 2018 Dec; 8(1):17679. PubMed ID: 30518941 [TBL] [Abstract][Full Text] [Related]
15. Major depletion of insulin sensitivity-associated taxa in the gut microbiome of persons living with HIV controlled by antiretroviral drugs. Belda E; Capeau J; Zucker JD; Chatelier EL; Pons N; Oñate FP; Quinquis B; Alili R; Fellahi S; Katlama C; Clément K; Fève B; Jaureguiberry S; Goujard C; Lambotte O; Doré J; Prifti E; Bastard JP BMC Med Genomics; 2024 Aug; 17(1):209. PubMed ID: 39138568 [TBL] [Abstract][Full Text] [Related]
16. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon. Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858 [TBL] [Abstract][Full Text] [Related]
17. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370 [TBL] [Abstract][Full Text] [Related]
18. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
19. Determinants of switch to paediatric second-line antiretroviral therapy after first-line failure in Cameroon. Njom-Nlend AE; Efouba N; Brunelle Sandie A; Fokam J Trop Med Int Health; 2021 Aug; 26(8):927-935. PubMed ID: 33905593 [TBL] [Abstract][Full Text] [Related]
20. Alterations of the gut microbiome in HIV infection highlight human anelloviruses as potential predictors of immune recovery. Boukadida C; Peralta-Prado A; Chávez-Torres M; Romero-Mora K; Rincon-Rubio A; Ávila-Ríos S; Garrido-Rodríguez D; Reyes-Terán G; Pinto-Cardoso S Microbiome; 2024 Oct; 12(1):204. PubMed ID: 39420423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]